Poly ADP-ribose polymerase (PARP) plays a critical role in many cellular processes such as
DNA damage repair, gene transcription and cell apoptosis. Therefore, targeting PARP …

Despite some advances in targeted therapeutics of human cancers, curative cancer
treatment still remains a tremendous challenge due to the occurrence of drug resistance. A …

Poly (ADP-ribose) polymerase (PARP) inhibitors have been approved for the treatment of
breast cancer (BC) with breast cancer susceptibility (BRCA) gene mutation. Leveraging new …

Abstract Poly (ADP-ribose) polymerase-1 (PARP-1) is one of the key members of DNA repair
enzymes that is responsible for the repair of DNA single-strand breaks. Inhibition of PARP-1 …

PARP-1/2 inhibitors have become an important therapeutic strategy for the treatment of HR-
deficient tumors. However, discovery of new inhibitors with an improved and distinct …

A new route for the synthesis of quinazolin-2, 4 (1 H, 3 H)-diones and thieno [2, 3-d]
pyrimidine-2, 4 (1 H, 3 H)-diones substituted by pyridyl/quinolinyl moiety in position 3 has …

Currently available PARP inhibitors are mainly used for the treatment of BRCA-mutated
triple-negative breast cancer (TNBC), with a narrow application range of approximately 15 …

Introduction PARP inhibitors block the DNA-repairing mechanism of PARP and represent a
promising class of anti-cancer therapy. The last decade has witnessed FDA approvals of …

Abstract Poly (ADP-ribose) polymerase 1 (PARP1) inhibitors can selectively kill homologous
recombination (HR) deficient cancer cells and elicit anticancer effect through a mechanism …

The global burden of colorectal cancer (CRC) has rapidly increased in recent years.
Dysregulated cholesterol homeostasis facilitated by extracellular matrix (ECM) remodeling …